Moomoo AIのまとめ
Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
バイオテクノロジーの臨床段階の企業であるSenti Biosciencesは、2023年12月31日を終了した年度の純損失が7,110万ドルで、前年度の5,820万ドルから増加しました。同社の現金、現金同等物、および短期投資は、2023年12月31日時点で3,590万ドルに減少し、前年度の9,860万ドルから減少しました。この年の営業費用は9,530万ドルで、そのうち研究開発費用は3,220万ドルを占めました。同社は、アラメダ施設をGeneFabに売却して2190万ドルの利益を認識し、長期的な営業費用も削減されました。Senti Biosciencesは、製品販売から売上高を生み出しておらず、...すべて展開
バイオテクノロジーの臨床段階の企業であるSenti Biosciencesは、2023年12月31日を終了した年度の純損失が7,110万ドルで、前年度の5,820万ドルから増加しました。同社の現金、現金同等物、および短期投資は、2023年12月31日時点で3,590万ドルに減少し、前年度の9,860万ドルから減少しました。この年の営業費用は9,530万ドルで、そのうち研究開発費用は3,220万ドルを占めました。同社は、アラメダ施設をGeneFabに売却して2190万ドルの利益を認識し、長期的な営業費用も削減されました。Senti Biosciencesは、製品販売から売上高を生み出しておらず、遺伝子回路プラットフォーム技術および製品候補の臨床開発を進めるにあたり、損失が継続する見込みであり、経費も増大すると予想されています。同社の将来の計画には、SENTI-202の臨床開発に重点を置き、SENTI-301Aプログラムを中国のCelestと提携することが含まれています。Senti Biosciencesは、追加資金なしに次の12か月を超えて持続する能力について懸念を表明しています。
役に立った
役に立たない
